medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2018, Number 3

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2018; 34 (3)

Molecular biology in the diagnostic accuracy of leukemia

Amor VAM, Hernández MLL, Díaz ACA, Fernández ML, Ruíz MV, Garrote SH

Language: Spanish
References: 16
Page: 1-7
PDF size: 265.58 Kb.


ABSTRACT

Cytogenetic and molecular studies have correlated the presence of certain chromosomal and molecular anomalies with leukemia and lymphomas specific types. These evidences have allowed the progressive improvement of the system of classification of the oncohematological entities. Currently, the presence of certain cytogenetic or molecular anomalies is sufficient to identify specific entities and, in some occasions, the diagnostic changes after an integral analysis of cytomorfologic, cytogenetic and molecular studies. T This report aims to highlight the importance of molecular study when cytomorphology is complex and leads to erroneous diagnoses. Through polymerase chain reaction, prior reverse transcription of the RNA isolated from medullary blood, four biomarkers were studied: the fusion genes AML1-ETO, BCR-ABL, CBFβ-MYH11 and PML-RARα. Fourteen patients with initial diagnosis of: promyelocytic leukemia (n= 6), acute leukemia without lineage definition (n= 3) and chronic myeloid leukemia in myeloid blastic crisis or acute myeloid leukemia (AML) (n= 5) were studied. At the end of the molecular characterization all were diagnosed as AML. These results enlightened the role of the molecular studies in the classification of leukemia, which permit the patient receives the more appropriate treatment and achieve a better response.


REFERENCES

  1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, GralnickHR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) cooperative group. Br J Haematol. 1976 Aug;33(4):451-8.

  2. Vardiman JW, Lee Harris N, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100:2292-302. doi:10.1182/blood-2002-04-1199

  3. Bennour A, Saad A, Sennana H. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays. Crit Rev Oncol Hematol. 2016 Jan;97:263-74. doi: 10.1016/j.critrevonc.2015.08.020.

  4. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocyticleukemia. N Engl J Med. 2013 Jul;369(2):111-21. doi: 10.1056/NEJMoa1300874

  5. De Braekeleer E, Douet-Guilbert N, De Braekeleer M. RARA fusion genes in acute promyelocytic leukemia: a review. Expert Rev Hematol. 2014;7(3):347-57.

  6. Prada-Arismendy J, Arroyave JC, Röthlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31:63-76.

  7. Mosna F, Gottardi M. Stem cell modeling of core binding factor acute myeloid leukemia. StemCellsInt. 2016;2016:7625827.doi: 10.1155/2016/7625827

  8. Duployez N, Willekens C, Marceau-Renaut A, Boudry-labis E. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert Rev Hematol. 2015;8(1):43-56.

  9. Terstrappen LW, Safford M, Loken MR. Flow cytometric analysis of human bone marrow. III. Neutrophil maturation. Leukemia. 1990;4:657-63.

  10. Mrózek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-36.

  11. Thompson MA. Molecular genetics of acute leukemia. In: Greer JP, Foerster J, Rodgers GM, eds. Wintrobe's Clinical Hematology. 12th ed. Philadelphia: Lippincott Williams & Wilkins; 2009. p. 1791-807.

  12. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French- American-British Cooperative Group. Ann Intern Med. 1985 Oct;103(4):620-5.

  13. Swerdlow S, Campo E, Harris N, editors. WHO classification of tumors of haematopoietic and lymphoid tissue. 4th ed. Lyon, France: IARC Press; 2008.

  14. Arber DA, Orazi A, Hasserjian R, Thiele J, BorowitzMJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127:2391-405.

  15. Van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of BIOMED-1 Concerted Action. Leukemia. 1999 Dec;13(12):1901-28.

  16. Mauricio JF. Biología molecular aplicada al diagnóstico clínico molecular. Rev Med Clin Las Condes 2015;26:788-93. Doi: 10.1016/j.rmclc.2015.11.007.




2020     |     www.medigraphic.com